Expanded Access for IMMU-132
NCT04320693 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2021-08-19
Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to IMMU-132.
Conditions
- Metastatic Triple-Negative Breast Carcinoma
Interventions
- DRUG
-
IMMU-132
IMMU-132 will be administered as an intravenous infusion on Days 1 and 8 of 21-day treatment cycles
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer
NCT00640861 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
NCT03387085 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
IMCgp100 in Advanced Unresectable Melanoma
NCT01209676 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment
NCT03706625 ·Status: COMPLETED
-
Efficacy of Interleukin-2 in Triple Negative Breast Cancer
NCT05821686 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Personalized Vaccine for Cancer Immunotherapy
NCT04879888 ·Status: COMPLETED ·Phase: PHASE1
-
Immunotherapy of Stage III/IV Melanoma Patients
NCT00112242 ·Status: COMPLETED ·Phase: PHASE1
-
Immunotherapy in Treating Patients With Metastatic Breast Cancer
NCT00003432 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Neo-adjuvant Immunotherapy in Patients With Localized Melanoma
NCT07230613 ·Status: RECRUITING ·Phase: PHASE2
-
Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)
NCT05259319 ·Status: RECRUITING ·Phase: PHASE1
-
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
NCT00436254 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg)
NCT01082887 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
NCT00001832 ·Status: COMPLETED ·Phase: PHASE2
-
Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients
NCT01308294 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Neo-adjuvant Immunotherapy Master Trial for Localized Cancers
NCT07262489 ·Status: RECRUITING ·Phase: PHASE2
-
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
NCT01026051 ·Status: TERMINATED ·Phase: PHASE2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
NCT03935893 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection
NCT00668382 ·Status: COMPLETED ·Phase: PHASE1
-
Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available
NCT00768391 ·Status: COMPLETED ·Phase: PHASE1
-
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
NCT04013854 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT03412877 ·Status: RECRUITING ·Phase: PHASE2
-
Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers
NCT00095862 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
ImmuniCell® in Patients With Advanced Cancers
NCT02459067 ·Status: TERMINATED ·Phase: PHASE2
-
Vaccine Treatment for Advanced Breast Cancer
NCT00090480 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
NCT06324240 ·Status: RECRUITING ·Phase: PHASE1